Charles River Laboratories International, Inc. has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash. MPI is a non-clinical CRO providing testing services to biopharmaceutical and medical device companies worldwide. The acquisition expands Charles River’s client base, providing access to growing end markets, builds scale, and expands its service portfolio, adding ototoxicity and abuse liability capabilities, and capabilities in general toxicolo...